Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ligand Licenses DARA Program to Retrophin
Potential for over $75 million in milestone payments to Ligand plus royalties Retrophin plans to develop DARA for rare nephropathies and other indications
View HTML
Toggle Summary Retrophin, LLC Completes Series A Financing
Proceeds will be used to advance pipeline of rare-disease drug candidates
View HTML
Toggle Summary Retrophin and St. Jude Children’s Research Hospital to Collaborate on Rare Disease Research Program
Program led by Dr. Suzanne Jackowski will test Retrophin replacement therapy library for treatment of PKAN, a rare neurodegenerative disease
View HTML
Toggle Summary Retrophin Completes Reverse Merger With Desert Gateway, Inc.
Creates publicly traded biotechnology company
View HTML
Toggle Summary Retrophin to Present at the 15th Annual BIO CEO & Investor Conference
Clinical and corporate updates to be shared February 12 at 3:30 p.m.
View HTML
Toggle Summary Retrophin Raises $10.0 Million in Private Placement
Proceeds will be used to advance pipeline of rare-disease drug candidates
View HTML
Toggle Summary Retrophin to Present at 25th Annual ROTH Conference
Clinical and corporate updates to be provided March 19 at 2:30 p.m. PT
View HTML
Toggle Summary Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN
New York, NY (March 11, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results
View HTML
Toggle Summary Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
Overview of RE-024 for PKAN presented
View HTML
Toggle Summary Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Brings wealth of clinical research and regulatory submission expertise to help advance pipeline
View HTML